SEC Form 4 · accession 0001209191-17-027470
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Haqq
Officer — EVP, R&D & Chief Scientific Of
Period of report
Apr 17, 2017
Accepted (ET)
Apr 19, 2017 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 17, 2017 | S | 6,000 | $17.28 | D | 380,855 | D | |
| Common StockF3 | holding | — | — | — | 17,312 | I | See footnote | |
| Common StockF4 | holding | — | — | — | 2,688 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.00 to $17.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- F4The shares are held by The Havenside Trust, of which the Reporting Person is trustee.